Literature DB >> 11325445

Radiotherapy for advanced adenoid cystic carcinoma: neutrons, photons or mixed beam?

P E Huber1, J Debus, D Latz, D Zierhut, M Bischof, M Wannenmacher, R Engenhart-Cabillic.   

Abstract

PURPOSE: To compare retrospectively radiotherapy with neutrons, photons, and a photon/neutron mixed beam in patients with advanced adenoid cystic carcinoma of the head and neck. Local control, survival, distant failure, and complications were analyzed.
MATERIALS AND METHODS: Between 1983 and 1995, 75 patients with inoperable, recurrent, or incompletely resected adenoid cystic carcinoma of the head and neck received radiotherapy that consisted of either fast 14.1 MV DT neutrons (median dose 16 neutron Gy), linac-based photon irradiation (median dose 64 photon Gy), or both (median dose 8 neutron Gy and 32 photon Gy). Follow-up ranged from 1 to 160 months (median 51 months), and the surviving patients had a minimum follow-up of 3 years at the time of analysis.
RESULTS: The actuarial 5-year local control was 75% for neutrons, and 32% for both mixed beam and photons (P = 0.015, log-rank). This advantage for neutrons in local control was not transferred to significant differences in survival (P > 0.1). The survival is dictated by the tumor diseases due to distant metastases occurring in 29 (39%) of the 75 patients. Positive lymph nodes were the only significant factor (P = 0.001) associated with the development of distant metastases although negative lymph nodes did not predict absence of distant metastases, but predicted a delay of occurrence. In multivariate analysis postoperative radiotherapy (P = 0.003) and small tumor size (P = 0.01) were associated with high local control, while primary therapy (P = 0.006) and negative lymph nodes (P = 0.01) were associated with longer survival. While acute toxicity was similar in all three radiotherapy groups, severe late grade 3 and 4 toxicity tended to be more prevalent (P > 0.1) with neutrons (19%) than with mixed beam (10%) and photons (4%).
CONCLUSION: Fast neutron radiotherapy provides higher local control rates than a mixed beam and photons in advanced, recurrent or not completely resected adenoid cystic carcinoma of the major and minor salivary glands. Neutron radiotherapy can be recommended in patients with bad prognosis with gross residual disease (R2), with unresectable tumors, or inoperable tumors. The type of radiation does not impact survival, which is dominated by the high number of distant metastases.

Entities:  

Mesh:

Year:  2001        PMID: 11325445     DOI: 10.1016/s0167-8140(00)00273-5

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  38 in total

1.  Adenoid cystic carcinoma presenting as an ulcer on the floor of the mouth: a rare case report.

Authors:  Saba Khan; Khalid Agwani; Puneet Bhargava; Sreeja P Kumar
Journal:  J Korean Assoc Oral Maxillofac Surg       Date:  2014-10-24

Review 2.  Review of clinical experience with ion beam radiotherapy.

Authors:  A D Jensen; M W Münter; J Debus
Journal:  Br J Radiol       Date:  2011-03-22       Impact factor: 3.039

Review 3.  Re-irradiation with protons or heavy ions with focus on head and neck, skull base and brain malignancies.

Authors:  Katharina Seidensaal; Semi Ben Harrabi; Matthias Uhl; Juergen Debus
Journal:  Br J Radiol       Date:  2019-11-12       Impact factor: 3.039

Review 4.  Cervical lymph node metastasis in adenoid cystic carcinoma of oral cavity and oropharynx: A collective international review.

Authors:  Carlos Suárez; Leon Barnes; Carl E Silver; Juan P Rodrigo; Jatin P Shah; Asterios Triantafyllou; Alessandra Rinaldo; Antonio Cardesa; Karen T Pitman; Luiz P Kowalski; K Thomas Robbins; Henrik Hellquist; Jesus E Medina; Remco de Bree; Robert P Takes; Andrés Coca-Pelaz; Patrick J Bradley; Douglas R Gnepp; Afshin Teymoortash; Primož Strojan; William M Mendenhall; Jean Anderson Eloy; Justin A Bishop; Kenneth O Devaney; Lester D R Thompson; Marc Hamoir; Pieter J Slootweg; Vincent Vander Poorten; Michelle D Williams; Bruce M Wenig; Alena Skálová; Alfio Ferlito
Journal:  Auris Nasus Larynx       Date:  2016-03-24       Impact factor: 1.863

Review 5.  Adenoid cystic carcinoma: focus on heavy ion therapy and molecular imaging.

Authors:  Angelo Castello; Laura Olivari; Egesta Lopci
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-02-05

6.  Parotid carcinoma: Current diagnostic workup and treatment.

Authors:  Vincent L M Vander Poorten; Francis Marchal; Sandra Nuyts; Paul M J Clement
Journal:  Indian J Surg Oncol       Date:  2010-11-21

7.  [Adenoid cystic carcinoma of the oropharynx. Brachytherapy for the treatment of local recurrences].

Authors:  H Badakhshi; S Marnitz; H Scherer; V Budach; A Haisch
Journal:  HNO       Date:  2008-03       Impact factor: 1.284

8.  Combined treatment of malignant salivary gland tumours with intensity-modulated radiation therapy (IMRT) and carbon ions: COSMIC.

Authors:  Alexandra D Jensen; Anna Nikoghosyan; Christine Windemuth-Kieselbach; Jürgen Debus; Marc W Münter
Journal:  BMC Cancer       Date:  2010-10-11       Impact factor: 4.430

Review 9.  Contemporary management of tumors of the salivary glands.

Authors:  Joseph M Scianna; Guy J Petruzzelli
Journal:  Curr Oncol Rep       Date:  2007-03       Impact factor: 5.075

10.  [Malignant epithelial salivary gland tumors. Clinical review of 2 decades].

Authors:  H Kokemüller; N Brüggemann; P Brachvogel; A Eckardt
Journal:  Mund Kiefer Gesichtschir       Date:  2004-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.